0.9433
price down icon7.52%   -0.0767
after-market Handel nachbörslich: .94 -0.0033 -0.35%
loading
Schlusskurs vom Vortag:
$1.02
Offen:
$0.98
24-Stunden-Volumen:
427.40K
Relative Volume:
0.48
Marktkapitalisierung:
$113.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.73M
KGV:
-7.2562
EPS:
-0.13
Netto-Cashflow:
$-3.92M
1W Leistung:
-15.78%
1M Leistung:
-17.97%
6M Leistung:
-5.67%
1J Leistung:
+111.17%
1-Tages-Spanne:
Value
$0.8762
$1.0299
1-Wochen-Bereich:
Value
$0.8762
$1.13
52-Wochen-Spanne:
Value
$0.41
$1.91

Tiziana Life Sciences Ltd Stock (TLSA) Company Profile

Name
Firmenname
Tiziana Life Sciences Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
9
Name
Twitter
@tizianals
Name
Nächster Verdiensttermin
2024-05-27
Name
Neueste SEC-Einreichungen
Name
TLSA's Discussions on Twitter

Vergleichen Sie TLSA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TLSA
Tiziana Life Sciences Ltd
0.9433 113.69M 0 -13.73M -3.92M -0.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-12-22 Eingeleitet B. Riley Securities Buy
2018-12-17 Eingeleitet Laidlaw Buy

Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten

pulisher
Apr 02, 2025

TLSATiziana Life Sciences Ltd Com Latest Stock News & Market Updates - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Small cap wrap: Zero Candida, Midnight Sun Mining, Tiziana Life Sciences, Trust Stamp... - Proactive Investors

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins - Proactive financial news

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Major Breakthrough: Johns Hopkins Launches Novel Nasal Treatment in Phase 2 MS Trial - Stock Titan

Apr 02, 2025
pulisher
Mar 26, 2025

Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis - Yahoo Finance

Mar 26, 2025
pulisher
Mar 25, 2025

Small cap wrap: Northern Superior Resources, Tiziana Life Sciences, Alternus Clean Energy... - Proactive Investors

Mar 25, 2025
pulisher
Mar 25, 2025

Multiple sclerosis Clinical Trials and Studies 2025: EMA, PDMA, - openPR

Mar 25, 2025
pulisher
Mar 25, 2025

Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS - Proactive Investors

Mar 25, 2025
pulisher
Mar 25, 2025

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Yale Launches Groundbreaking Intranasal MS Treatment Trial: Tiziana's Innovation in Focus - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 MillionSEC Filing -March 24, 2025 at 05:22 pm EDT - Marketscreener.com

Mar 24, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences CEO to present at 37th Annual ROTH Conference - Proactive Investors UK

Mar 17, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences to Present at the 37th Annual Roth Conference - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Tiziana Life Sciences Reveals Growth Strategy at Major ROTH ConferenceKey Updates Expected - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - The Manila Times

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Requirements - Nasdaq

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule - MENAFN.COM

Mar 14, 2025
pulisher
Mar 14, 2025

Tiziana Life Sciences Regains Nasdaq Compliance, Secures Continued Listing - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St

Mar 13, 2025
pulisher
Mar 10, 2025

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease - Informazione.it

Mar 10, 2025
pulisher
Mar 10, 2025

Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases? - RTTNews

Mar 10, 2025
pulisher
Mar 07, 2025

Tiziana Life Sciences stock soars to 52-week high of $1.75 - Investing.com

Mar 07, 2025
pulisher
Mar 06, 2025

Democrat-led states join legal fight over Trump's mass firings of federal workers -March 06, 2025 at 10:38 pm EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA - DRP Journal

Mar 06, 2025
pulisher
Mar 05, 2025

Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment - Seeking Alpha

Mar 05, 2025
pulisher
Mar 04, 2025

Sector Update: Health Care -March 04, 2025 at 03:39 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana submits FDA investigational new drug application - Proactive Investors UK

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate -March 04, 2025 at 09:03 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Could This Intranasal Therapy Change ALS Treatment? Tiziana Seeks FDA Approval - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN

Mar 03, 2025
pulisher
Mar 02, 2025

Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 27, 2025

Tiziana stock jumps 12% on TBI drug study publication - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors UK

Feb 27, 2025
pulisher
Feb 27, 2025

Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive financial news

Feb 27, 2025
pulisher
Feb 27, 2025

Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals - Proactive Investors UK

Feb 27, 2025
pulisher
Feb 27, 2025

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Can Tiziana's Nasal Therapy Revolutionize Traumatic Brain Injury Treatment? New Study Says Yes - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive… - Informazione.it

Feb 27, 2025
pulisher
Feb 26, 2025

Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive financial news

Feb 26, 2025
pulisher
Feb 25, 2025

Tiziana Life Sciences nearing completion of long COVID study on foralumab - Proactive Investors UK

Feb 25, 2025
pulisher
Feb 25, 2025

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Can This Nasal Therapy Solve Long COVID? Tiziana's Breakthrough Approach Targets Brain Inflammation - StockTitan

Feb 25, 2025
pulisher
Feb 22, 2025

Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World

Feb 22, 2025

Finanzdaten der Tiziana Life Sciences Ltd-Aktie (TLSA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):